Enanta Pharmaceuticals Inc. (NASDAQ:ENTA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday.

According to Zacks, “Enanta Pharmaceuticals, Inc. is a biotechnology company. It engages in the research and development of molecule drugs for the treatment of infectious diseases such as hepatitis C virus, respiratory tract infections, intravenous and oral treatments. Enanta Pharmaceuticals, Inc. is headquartered in Watertown, Massachusetts. “

A number of other research analysts have also issued reports on ENTA. Robert W. Baird restated an “outperform” rating and set a $27.00 price objective (up previously from $22.00) on shares of Enanta Pharmaceuticals in a research report on Tuesday, November 22nd. JPMorgan Chase & Co. set a $26.00 price objective on Enanta Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, August 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus target price of $27.29.

Enanta Pharmaceuticals (NASDAQ:ENTA) remained flat at $31.29 during mid-day trading on Tuesday. 260,034 shares of the company’s stock traded hands. The firm has a 50 day moving average of $26.43 and a 200 day moving average of $24.25. The firm has a market capitalization of $595.61 million, a P/E ratio of 27.69 and a beta of 0.61. Enanta Pharmaceuticals has a 1-year low of $20.39 and a 1-year high of $35.06.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings data on Monday, November 21st. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.14) by $0.05. Enanta Pharmaceuticals had a return on equity of 8.10% and a net margin of 24.55%. The business earned $12.80 million during the quarter, compared to analyst estimates of $13.56 million. During the same quarter in the previous year, the firm posted $0.29 EPS. The business’s revenue for the quarter was down 11.1% compared to the same quarter last year. On average, equities analysts expect that Enanta Pharmaceuticals will post $1.08 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Enanta Pharmaceuticals Inc. (ENTA) Downgraded to “Hold” at Zacks Investment Research” was posted by Financial Market News and is the propert of of Financial Market News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The original version of this article can be viewed at http://www.financial-market-news.com/enanta-pharmaceuticals-inc-enta-downgraded-to-hold-at-zacks-investment-research/1209132/.

Several hedge funds have recently bought and sold shares of the company. SECOR Capital Advisors LP purchased a new stake in Enanta Pharmaceuticals during the second quarter worth approximately $947,000. Ameriprise Financial Inc. increased its stake in Enanta Pharmaceuticals by 68.1% in the second quarter. Ameriprise Financial Inc. now owns 102,795 shares of the company’s stock worth $2,267,000 after buying an additional 41,650 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in Enanta Pharmaceuticals by 57.1% in the second quarter. PNC Financial Services Group Inc. now owns 14,042 shares of the company’s stock worth $310,000 after buying an additional 5,103 shares in the last quarter. GSA Capital Partners LLP increased its stake in Enanta Pharmaceuticals by 8.3% in the second quarter. GSA Capital Partners LLP now owns 137,240 shares of the company’s stock worth $3,026,000 after buying an additional 10,565 shares in the last quarter. Finally, Emerald Acquisition Ltd. purchased a new stake in Enanta Pharmaceuticals during the second quarter worth approximately $2,420,000. 68.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create molecule drugs primarily for the treatment of viral infections and liver diseases. The Company is engaged in discovering and developing inhibitors designed for use against the hepatitis C virus (HCV), as well as compounds for non-alcoholic steatohepatitis (NASH) and primary biliary cirrhosis (PBC).

5 Day Chart for NASDAQ:ENTA

Get a free copy of the Zacks research report on Enanta Pharmaceuticals (ENTA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.